Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDA Supplement Review Timeline Hinges On Need For Inspection

Executive Summary

FDA notes that it may not be evident right away whether an inspection will be required as part of the review.

You may also be interested in...

FDA Outlines Criteria For Approving Manufacturing Supplements Under GDUFA

Generic drug manufacturers are told by FDA when and how it will accept prior approval supplements under GDUFA.

Foreign Regulator Training Only Provides Short-Term Gains, FDA Official Says

Acting Deputy Commissioner John Taylor says training often is for reactive work, and FDA must shift to a more proactive strategy and ensure strong regulatory laws, equipment and organizations around the world.

Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

Draft commitment letter could be first step down globalization road in which FDA relies more on foreign governments to boost manufacturing oversight.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts